Bringing Xeljanz® to More Patients Worldwide
While significant advances have been made in the treatment of chronic inflammatory conditions, new treatments and mechanisms of action are needed for these diseases, which can be debilitating, distressing and difficult to manage. In 2018, Xeljanz® (tofacitinib) was approved by the European Medicines Agency (EMA) for the treatment of active psoriatic arthritis (PsA) and moderately to severely active ulcerative colitis (UC), an important step forward for patients in need of new treatment options. Today, Xeljanz is approved in more than 80 countries for the treatment of rheumatoid arthritis (RA), over 40 countries for the treatment of PsA and in more than 70 countries for the treatment of UC.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families